CAPS — Capstone Therapeutics Income Statement
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $9.76m
- $12.13m
Annual income statement for Capstone Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2015 December 31st | 2016 December 31st | 2017 December 31st | R2018 December 31st | 2019 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Total Operating Expenses | 2.94 | 1.58 | 1.68 | 0.554 | 0.762 |
| Operating Profit | -2.94 | -1.58 | -1.68 | -0.554 | -0.762 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Net Income Before Taxes | -2.96 | -1.67 | -1.79 | -0.802 | -1.02 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -2.77 | -1.61 | 17.2 | -0.753 | -0.999 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Extraordinary Items | |||||
| Net Income | -2.77 | -0.663 | -1.75 | -0.38 | -2.07 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -2.77 | -0.663 | -1.75 | -0.38 | -2.07 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -67.8 | -16.2 | 366 | -13.8 | -6.58 |
| Dividends per Share |